inno shred glp-1 reviews Watch Before You Buy: Dad Review of Supplement on Amazon Live Inno Shred GLP-1 Thermogenic Fat

Studies in rodents have shown that GLP-1 receptor agonists, including semaglutide, cause dose-dependent and treatment-duration-dependent thyroid C-cell tumors

Rosenberg TL, Kelley K, Dowdall JR, Replogle WH, Liu JC, Raol NP, Zafereo ME

FDA-APPROVED INDICATIONS Type 2 diabetes As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus Limitations of use: has not been studied in patients with a history of pancreatitis TYPE 2 DIABETES RCT SURPASS-2 trial - Tirzepatide vs Semaglutide in Patients with Type 2 Diabetes, NEJM (2021) [PubMed abstract] The SURPASS-2 trial enrolled 1879 adults with type 2 diabetes who were inadequately controlled with metformin at a dose of at least 1500 mg per day Main inclusion criteria Age 18 years T2DM uncontrolled with metformin at 1500 mg/day A1C of 7 - 10.5% BMI 25 and stable for 3 months Main exclusion criteria Type 1 diabetes GFR 50 ng/L

- trimethylamine-N-oxide (TMAO)

This is bad

Collagen I-DDR1 signaling promotes hepatocellular carcinoma cell stemness via Hippo signaling repression